Experimental vaccine aims to train immune system to fight returning melanoma
NCT ID NCT01861938
Summary
This study tested a modified tumor cell vaccine designed to boost the body's immune system to attack melanoma cells. It was intended for patients with high-risk melanoma or those with a small amount of disease remaining after initial treatment. The goal was to see if the vaccine could improve survival and delay the cancer's return by strengthening the immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK HLA-A2+ MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.